Pancreatic Cancer Clinical Trials in Philadelphia, Pennsylvania

8 studies are recruiting for pancreatic cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   72 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence

   This pilot study is testing whether a special type of ultrasound called contrast-enhanced ultrasound (CEUS) can help detect if pancreatic cancer has come back after surgery. People may be eligible to participate if they had surgery to remove pancreatic ductal adenocarcinoma (PDAC) from the head or …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07910383 on ClinicalTrials.gov

3. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   86 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07252232 on ClinicalTrials.gov

4. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   23 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

5. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

6. Prehabilitation in High-risk Oncologic Surgery

   The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery. Prehabilitation is supportive care given before surgery to help patients prepare physically, nutritional…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT07638410 on ClinicalTrials.gov

7. Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

   The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT02478892 on ClinicalTrials.gov

8. Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

   Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   CivaTech Oncology

   See if you can join NCT02843945 on ClinicalTrials.gov